Maito, Nasra B.
HRN: 10-14-01 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/09/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
01/09/2023
01/16/2023
IV
270mg
Q8hours
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes